SCHEMBL470124

SCHEMBL470124

COc1ccc(I)cc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.54
CA12 O43570 3/20 0.54
CA1 P00915 3/20 0.54
CA7 P43166 3/20 0.54
CA9 Q16790 3/20 0.54
CA14 Q9ULX7 3/20 0.54
ACHE P22303 1/20 0.54
TSHR P16473 3/20 0.46
CYP1A2 P05177 2/20 0.46
ALDH1A1 P00352 2/20 0.46
POLB P06746 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
MAPK1 P28482 1/20 0.46
CA4 P22748 2/20 0.46
PDE4A P27815 1/20 0.45
NR3C1 P04150 1/20 0.45
CA6 P23280 1/20 0.45
TPMT P51580 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31277237 1.00 CA2 (0.54) CA2CA12CA1CA7CA9
SCHEMBL16174318 0.86 CA2 (0.41) CA2CA12CA1CA7CA9
SCHEMBL31098551 0.83 PDE4A (0.50) TSHRALDH1A1MAPK1PDE4AAPP
SCHEMBL8123915 0.83 PDE4A (0.50) TSHRALDH1A1MAPK1PDE4AAPP
SCHEMBL4152456 0.83 PDE4B (0.42) CA2CA12CA1CA7CA9
SCHEMBL11439070 0.83 KDM4E (0.59) TSHRALDH1A1MAPK1PDE4AAPP
SCHEMBL20553872 0.83 CA2 (0.39) CA2CA12CA1CA7CA9
SCHEMBL197234 0.82 APP (0.38) CA2CA12CA1CA7CA9
SCHEMBL482383 0.82 CA2 (0.41) CA2CA12CA1CA7CA9
SCHEMBL3548000 0.81 CYP1A2 (0.40) CA2CA12CA1CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110615801-A Preparation method and application of triazine compound with polyvinyl chloride light stabilization effect 河南龙湖生物技术有限公司 2019-12-27 CN claimed
CN-110204555-A The preparation method and application of compound in triazine class with polyvinyl chloride light stabilization 河南龙湖生物技术有限公司 2019-09-06 CN claimed
CN-105732333-B A kind of preparation method of the trichloro-benzene of 1,2 dimethoxy, 4 iodobenzene 3,5,6 天津城建大学 2018-01-12 CN claimed
CN-105732333-A Preparation method of 1,2-dimethoxy-4-iodobenzene-3,5,6-trichlorobenzene 天津城建大学 2016-07-06 CN claimed
CN-101861325-A In the chemical reaction that the aryl boric acid that use replaces through the ortho position carries out, carboxylic acid is carried out organic catalysis activatory method UNIV ALBERTA 2010-10-13 CN claimed
CN-1330679-A Plastic moulding materials which can be detected by x-ray contrast BAYER AG (DE) 2002-01-09 CN claimed
EP-1155073-A1 PLASTIC MOULDING MATERIALS WHICH CAN BE DETECTED BY X-RAY CONTRAST Bayer Aktiengesellschaft (DE) 2001-11-21 EP claimed
WO-2000036002-A1 PLASTIC MOULDING MATERIALS WHICH CAN BE DETECTED BY X-RAY CONTRAST BAYER AKTIENGESELLSCHAFT (DE) 2000-06-22 WO claimed
EP-4743453-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION Pretzel Therapeutics, Inc. (US) 2026-05-20 EP disclosed
EP-4688796-A1 ARYL-HETEROCYCLE-PYRROLE CATALYSTS FOR OLEFIN POLYMERIZATION Dow Global Technologies LLC (US) 2026-02-11 EP disclosed
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 EP disclosed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 US disclosed
WO-2025015178-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION PRETZEL THERAPEUTICS, INC. (US) 2025-01-16 WO disclosed
US-12186313-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-01-07 US disclosed
US-5384068-A Switchable columnar liquid-crystalline systems HOECHST AKTIENGESELLSCHAFT (DE) 1995-01-24 US disclosed
US-4910200-A Agricultural fungicide CELAMERCK GMBH & CO. KG (DE) 1990-03-20 US disclosed
US-4910198-A Antiarrhythmia agent ORTHO PHARMACEUTICAL CORPORATION (US) 1990-03-20 US disclosed
US-4855426-A Process of preparing 1,5-epoxy-2,3,4,5-tetrahydro-1H-3-benzazepins ORTHO PHARMACEUTICAL CORPORATION (US) 1989-08-08 US disclosed
US-4761413-A CYTOPROTECTION, ANTISECRETORY AGENTS ORTHO PHARMACEUTICAL CORPORATION (US) 1988-08-02 US disclosed
US-4118507-A Benzodioxincarboxamide lipogenesis inhibitors SHELL OIL COMPANY (US) 1978-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12186313-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD CA2 3315/4885CA12 3332/4885CA1 3015/4885
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL CA2 4149/4885CA12 4075/4885CA1 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.